A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR)-Reference-Cited by-同舟云学术

A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR)

Published:2024-03-18 Issue:1 Volume:20 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Maestri Alvino¹,Park Su Eun²,Fernandes Fiona¹,Li Zhongyi “Lucy”¹,Kim Yae-Jean³,Kim Yun-Kyung⁴,Lee Jin⁵,Park Ji Young⁶,Kim Dong Hyun⁷,Yang GyongSeon⁸,Lim Hyunjung⁹,Kim Jin Oh⁸,Lupinacci Robert¹,Sterling Tina M.¹,Wilck Marissa¹^ORCID,Esteves-Jaramillo Alejandra¹,Banniettis Natalie¹

Affiliation:

1. MRL, Merck & Co., Inc., Rahway, NJ, USA

2. Department of Pediatrics, Pusan National University Children’s Hospital, Yangsan, Republic of Korea

3. Department of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Centre, Seoul, Republic of Korea

4. Department of Pediatrics, Korea University College of Medicine, Seoul, Republic of Korea

5. Department of Pediatrics, Incheon St. Mary’s Hospital, Incheon, Republic of Korea

6. Department of Pediatrics, Chung-Ang University Hospital, Seoul, Republic of Korea

7. Department of Pediatrics, Inha University Hospital, Incheon, Republic of Korea

8. Global Medical Scientific Affairs, MSD Korea, Seoul, Republic of Korea

9. Global Clinical Trial Operations, MSD Korea, Seoul, Republic of Korea

Funder

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2321035

Reference22 articles.

1. Serotype Distribution and Antimicrobial Resistance of Streptococcus pneumoniae Causing Invasive Pneumococcal Disease in Korea Between 2017 and 2019 After Introduction of the 13-Valent Pneumococcal Conjugate Vaccine

2. Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination

3. Center for Disease Control and Prevention. Pneumococcal disease. 2022 [accessed 2023 Jun 1]. https://www.cdc.gov/pneumococcal/clinicians/streptococcus-pneumoniae.html.

4. Impact of pneumococcal conjugate vaccine on pneumonia hospitalization and mortality in children and elderly in Ecuador: Time series analyses

5. Incidence of pneumococcal disease from 2003 to 2019 in children ≤17 years in England